Evaluate the expected performance of Exelixis (EXEL) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key ...

The genomics industry is set for growth due to advancements in personalized medicine, diagnostics, and biotech innovations.

Oppenheimer analysts downgraded Exelixis (NASDAQ:EXEL) stock from Outperform to Perform, adjusting the price target to $33.00 from the previous $41.00. The decision came amid concerns about the ...

I worked closely with NCI’s Investigational Drug Branch (IDB) from 1990-2016, including as a principal investigator of one of ...

Chicago Partners Investment Group LLC purchased a new position in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) in the ...

Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal study of ...

Exelixis, Inc. (NASDAQ:EXEL), a biopharmaceutical company focused on developing and commercializing novel therapies for difficult-to-treat cancers, has demonstrated resilience and growth potential in ...

Exelixis (EXEL) has recently gained traction in the rapidly growing oncology market with its promising pipeline and strong ...

Exelixis, Inc. (Nasdaq: EXEL) announced today that its fourth quarter and full year 2024 financial results will be released ...

Riverwater Partners, an investment management company, released its “Sustainable Value Strategy” Q4 2024 investor letter. A copy of the letter can be downloaded here. The strategy outperformed its ...

Barclays analyst Peter Lawson maintained a Hold rating on Exelixis (EXEL – Research Report) today and set a price target of $25.00. The ...